Trulicity Cost in Tennessee 2026: Prices, Insurance, Medicaid, and Your Cheapest Legal Options

What Does Trulicity Actually Cost in Tennessee in 2026?

The Eli Lilly wholesale acquisition cost for Trulicity sits at $931 per month for a four-pen carton (four weekly doses) at Tennessee retail pharmacies in 2026. Without insurance or a savings program, that is the cash price a patient pays at the counter. No generic dulaglutide has received FDA approval, so there is no cheaper bioequivalent option at chain pharmacies right now.

Prices vary slightly by pharmacy chain and city. A 2025 GoodRx survey of Tennessee zip codes found cash prices ranging from $892 to $966 per month depending on the dispensing pharmacy, with Costco Pharmacy and Mark Cuban's Cost Plus Drugs sometimes listing dulaglutide below the standard retail figure when supply is available. Always run a real-time price check through your specific pharmacy before filling.

Dulaglutide's mechanism involves once-weekly subcutaneous injection of a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, slows gastric emptying, and suppresses glucagon [1]. The FDA first approved Trulicity in September 2014 for adults with type 2 diabetes, and later expanded the label to include reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [2].

The REWIND trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 showed dulaglutide 1.5 mg once weekly reduced the composite MACE endpoint by 12% relative to placebo (hazard ratio 0.88 to 95% CI 0.79, 0.99, P<0.026), a finding that underpins its expanded label and makes it relevant for a large share of Tennessee's diabetic population [3]. Tennessee's adult diabetes prevalence was 14.4% in 2023, one of the highest rates in the country, according to the CDC [4].

Does TennCare (Tennessee Medicaid) Cover Trulicity?

TennCare does not cover Trulicity for type 2 diabetes as a standard benefit in 2026. This is the short answer, and it matters enormously for the roughly 1.6 million Tennesseans enrolled in TennCare.

The TennCare formulary favors older, less expensive diabetes agents. Metformin, sulfonylureas, and basal insulins are covered without restriction. Some GLP-1 receptor agonists appear on the preferred drug list for specific indications, but dulaglutide for type 2 diabetes is not among them without a successful prior authorization that meets strict medical necessity criteria. Physicians can submit a prior authorization request citing documented failure of preferred agents and documented cardiovascular comorbidity, but approval rates for non-preferred GLP-1 agents under TennCare remain low.

The American Diabetes Association's 2024 Standards of Medical Care designate GLP-1 receptor agonists as preferred agents when atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease is present [5]. That guidance may support a prior authorization argument, but TennCare's drug review committee is not bound by ADA recommendations. A prescribing physician should document all prior therapy trials, current HbA1c, and cardiovascular risk in the prior authorization letter.

For TennCare members who cannot obtain prior authorization approval, the most realistic paths are the Lilly patient assistance program (income-based, free drug), a licensed 503A compounding pharmacy, or switching to a covered GLP-1 agent if medically appropriate. Ozempic (semaglutide) has different formulary placement under some TennCare managed care plans and may be worth checking as an alternative [6].

How the Eli Lilly Savings Card Works in Tennessee

Commercially insured Tennessee patients may qualify for the Lilly Trulicity Savings Card, which can reduce monthly out-of-pocket costs to as low as $25 per fill for eligible patients. The mechanics matter.

The card covers the gap between your commercial insurance copay and a capped amount. Eli Lilly sets the cap at up to $150 per month in most program years, meaning your personal cost is $25, $150 depending on your plan's tier structure. The card does not work for patients enrolled in Medicare Part D, Medicaid, or any government-funded plan. Tennessee patients on TennCare, Medicare Advantage with Part D, or VA pharmacy benefits cannot use the commercial savings card.

To activate the card, visit Lilly's official savings program portal, confirm commercial insurance eligibility, and present the card at any Tennessee retail pharmacy. The pharmacist runs a real-time adjudication. If your insurance denies Trulicity entirely, the savings card cannot override that denial. The card only reduces cost-sharing, not the coverage decision itself.

Lilly also operates the Lilly Cares Foundation Patient Assistance Program for uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level. That program supplies Trulicity at no charge. Applications require income documentation and a prescriber's signature [7].

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm notes that cost and access barriers are among the top reasons patients discontinue GLP-1 therapy, and recommends that clinicians proactively identify savings programs at the time of prescribing [8].

Is Compounded Dulaglutide Legal in Tennessee?

Compounded dulaglutide from a state-licensed 503A pharmacy is legal in Tennessee. This is a nuanced legal position that requires careful reading.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients when a licensed prescriber provides a valid prescription [9]. Tennessee's Board of Pharmacy licenses and inspects 503A facilities. As of 2026, dulaglutide is not on the FDA's Demonstrably Difficult to Compound list, and it is not on the Category 1 or Category 2 lists that would restrict 503A compounding. That means a Tennessee 503A pharmacy can legally prepare patient-specific compounded dulaglutide upon receipt of a valid prescription.

503B outsourcing facilities operate under different rules. They supply hospitals and clinics in bulk and are registered with the FDA directly. A 503B facility cannot supply compounded dulaglutide to a retail patient without a specific patient prescription, unlike branded Trulicity which moves through normal wholesale channels. Patients should confirm their pharmacy's 503A licensure with the Tennessee Board of Pharmacy's public license lookup before filling a compounded GLP-1 prescription.

Quality differences between compounded and FDA-approved Trulicity are real. The branded autoinjector pen is a fixed-dose, pre-filled, factory-tested device. A compounded vial requires the patient to draw and self-inject, introducing more steps. The active pharmaceutical ingredient used in compounding must come from an FDA-registered supplier, but the finished product does not undergo the same bioequivalence testing as Trulicity. Patients should discuss these trade-offs with their prescriber.

Cost is the obvious driver. Several Tennessee-based telehealth platforms have partnered with licensed 503A pharmacies to supply compounded dulaglutide at prices ranging from $0 (fully covered under a telehealth subscription model) to $150, $250 per month, compared with the $931 Trulicity list price. These programs are legal where 503A licensure is confirmed and a valid individual prescription exists.

The HealthRX clinical team has developed the following decision framework for Tennessee patients weighing branded Trulicity against compounded dulaglutide from a 503A pharmacy. Start with insurance coverage: if your commercial plan covers Trulicity with the Lilly savings card bringing your cost to $150 or less per month, branded Trulicity is the lower-friction path. If you are uninsured and income-eligible, Lilly Cares supplies the drug free. If you are TennCare-enrolled with a denied prior authorization and your prescriber confirms no clinical contraindication to compounded product, a licensed 503A pharmacy is a legal, lower-cost option. Confirm 503A licensure on the Tennessee Board of Pharmacy website before the first fill.

Which Commercial Insurance Plans Cover Trulicity in Tennessee?

Coverage varies by plan, tier, and employer group. These are the general patterns for 2026.

BlueCross BlueShield of Tennessee includes dulaglutide on its formulary for commercial large-group plans, typically at Tier 3 with a prior authorization requirement confirming type 2 diabetes diagnosis and a trial of metformin. Cigna, Aetna, and UnitedHealthcare plans sold in Tennessee generally follow the same structure: Tier 3 or Tier 4, prior authorization required, step therapy through metformin and sometimes a sulfonylurea first.

Employers who self-fund their health plans (common among large Tennessee employers like FedEx, Nissan, and Hospital Corporation of America) set their own formularies and may cover or exclude Trulicity independently of the insurer's standard drug list. Always check your specific plan's Summary of Benefits and Coverage or call the pharmacy benefits manager (PBM) directly.

Medicare Part D plans sold in Tennessee by Humana, UnitedHealthcare, and Aetna each maintain separate formularies. Trulicity appears on several Part D plans at Tier 4 or Tier 5, where the 2026 out-of-pocket cap under the Inflation Reduction Act means Part D enrollees pay no more than $2,000 per year in total out-of-pocket drug costs [10]. For a patient whose only expensive drug is Trulicity, reaching the $2,000 cap mid-year and then paying $0 through December is a realistic scenario.

The FDA's current labeling for Trulicity specifies its approved indications, which insurance reviewers use to judge medical necessity [2]. A prescription written outside the approved indication (for example, weight loss only in a non-diabetic patient) will almost certainly be denied by commercial plans and Part D.

Can You Get a Trulicity Prescription via Telehealth in Tennessee?

Yes. Tennessee law permits telehealth prescribing of controlled and non-controlled medications, including GLP-1 receptor agonists like dulaglutide, when the prescriber holds a valid Tennessee medical license and meets standard-of-care documentation requirements.

The Tennessee Department of Health updated its telehealth rules in 2021 to align with a synchronous audio-visual encounter standard. A prescriber can establish a valid patient-physician relationship through a video visit, conduct a clinical assessment, review labs, and write a dulaglutide prescription without an in-person visit. That prescription can then be sent to a Tennessee retail pharmacy or a licensed 503A compounding pharmacy.

The ADA's 2024 Standards of Medical Care explicitly support telehealth as a delivery model for diabetes management, noting that telehealth may improve access in underserved areas [5]. Tennessee has significant rural populations, and telehealth GLP-1 prescribing addresses a genuine access gap. Counties like Hancock, Pickett, and Perry have limited endocrinology access; a telehealth visit closes that gap.

From a clinical safety standpoint, initiating dulaglutide via telehealth requires the same minimum work-up as an in-person visit: confirmed type 2 diabetes diagnosis (or documented clinical rationale if off-label), baseline HbA1c, renal function panel, and review of contraindications including personal or family history of medullary thyroid carcinoma or MEN2 syndrome [2]. The FDA label carries a black box warning for thyroid C-cell tumors based on rodent data, and prescribers must counsel patients on this risk regardless of visit modality.

Clinical Efficacy Data Every Tennessee Patient Should Know

Understanding why Trulicity costs what it costs starts with understanding what the drug actually does in large trials.

REWIND (N=9,901) remains the definitive cardiovascular outcomes trial for dulaglutide. Published in The Lancet in 2019, it enrolled patients with type 2 diabetes who had either established cardiovascular disease or two or more cardiovascular risk factors. Median follow-up was 5.4 years. Dulaglutide 1.5 mg once weekly reduced the primary MACE endpoint (nonfatal MI, nonfatal stroke, CV death) by 12% relative to placebo (HR 0.88 to 95% CI 0.79, 0.99) [3]. Secondary findings included a significant reduction in new or worsening nephropathy (HR 0.85, P<0.004) and a reduction in new macroalbuminuria [3].

The AWARD trial program, a series of eight phase 3 studies, established dulaglutide's glycemic efficacy. AWARD-5 (N=1,098 to 104 weeks) compared dulaglutide 1.5 mg against sitagliptin 100 mg; dulaglutide produced a mean HbA1c reduction of 0.99 percentage points more than sitagliptin at 52 weeks [11]. AWARD-11 (N=1,842) tested 3.0 mg and 4.5 mg doses, showing dose-dependent HbA1c reductions and weight loss that exceeded those of the approved 1.5 mg dose, data that informed Lilly's ongoing higher-dose development program [12].

Body weight reduction with dulaglutide 1.5 mg averages 2 to 3 kg over 26 weeks in clinical trials, modest compared with semaglutide 2.4 mg (STEP-1, N=1,961: 14.9% mean body weight reduction at 68 weeks) [13]. Patients primarily seeking weight loss, rather than glycemic control, may find semaglutide-based products a better clinical fit, and their prescriber should document that rationale clearly for insurance purposes.

Adverse events with dulaglutide are predominantly gastrointestinal: nausea (12 to 21% of patients), diarrhea (6 to 12%), vomiting (6 to 8%), and abdominal pain. These events are typically transient, peaking in the first four to eight weeks. Starting at 0.75 mg for four weeks before escalating to 1.5 mg reduces GI burden for most patients, as specified in the FDA label [2].

The Endocrine Society's 2023 Pharmacological Management of Type 2 Diabetes guideline recommends a GLP-1 receptor agonist with proven cardiovascular benefit (a class that includes dulaglutide) as a preferred add-on to metformin in patients with established or high cardiovascular risk, independent of HbA1c level [14].

How Tennessee Patients Can Reduce Trulicity Costs Step by Step

No single program works for every patient. These are the sequential steps to find the lowest legal cost.

First, confirm your diagnosis and indication. Insurance coverage and assistance programs both require documented type 2 diabetes. An HbA1c of 6.5% or above on two separate occasions, or a fasting glucose of 126 mg/dL or above, satisfies ADA diagnostic criteria [5].

Second, check your insurance formulary. Log into your plan's drug lookup tool or call the PBM. Ask for the step-therapy requirements and prior authorization criteria. Gather your prescriber's documentation of prior metformin use and current HbA1c before submitting.

Third, apply for the Lilly savings card if you have commercial insurance. The activation takes about five minutes online and is valid for 12 months. Reactivation is required annually.

Fourth, if you are uninsured or underinsured, apply to Lilly Cares. Processing takes two to four weeks; your prescriber's office can help submit the required paperwork [7].

Fifth, if TennCare denied coverage and you have a valid prescription, identify a Tennessee-licensed 503A compounding pharmacy. Verify the license on the Tennessee Board of Pharmacy public lookup. Ask the pharmacy for a certificate of analysis for the active pharmaceutical ingredient batch before your first fill.

Sixth, consider a telehealth GLP-1 platform. Several platforms operating legally in Tennessee bundle the prescriber visit, ongoing monitoring, and compounded dulaglutide into a monthly subscription below $200. Confirm that the platform's pharmacy partner holds a Tennessee 503A license.

The FDA's MedWatch program allows patients and providers to report quality or safety concerns about compounded products at 1-800-FDA-1088 or through the FDA website [15].

Monitoring Requirements After Starting Dulaglutide in Tennessee

Starting dulaglutide is not a set-and-forget decision. Prescribers in Tennessee, whether in-person or via telehealth, should schedule follow-up labs and clinical checks at standard intervals.

HbA1c should be measured at three months after initiation to assess glycemic response; the ADA defines adequate response as HbA1c at or below the individualized target, typically 7.0% for most non-pregnant adults [5]. A basic metabolic panel at three months catches early renal changes; dulaglutide's renal effects are generally protective, but acute GI adverse events can cause dehydration and transient creatinine elevation [2].

Patients with a history of pancreatitis should not use dulaglutide without specialist input. The FDA label specifies that dulaglutide should be discontinued if pancreatitis is suspected [2]. Prescribers should ask about upper abdominal pain that does not resolve within 48 hours and instruct patients to stop the medication and seek evaluation.

Thyroid nodule screening is not routinely required, but patients with a palpable thyroid mass or rapid thyroid growth should have ultrasound evaluation and endocrinology referral, as the rodent signal for C-cell tumors, while not confirmed in humans, obligates clinician vigilance [2].

Blood pressure and weight should be tracked at every visit. REWIND showed a modest blood pressure reduction with dulaglutide (approximately 1.5 mmHg systolic) alongside glycemic benefits [3]. Weight tracking over the first 12 weeks also helps identify patients unlikely to respond to dulaglutide for weight management, allowing a timely switch to a higher-efficacy agent if needed.

The National Institutes of Health maintains a resource on GLP-1 receptor agonist pharmacology that provides additional background for patients and clinicians reviewing mechanism and safety data [1].